A scientific forum open to all scientists interested in research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations.
The purpose of Cambridge New Therapeutics Forum (CamNTF) is to promote interactions between scientists at these organisations in order to improve opportunities for biotechnology research and development.
Starting from 2015 CamNTF will host early-evening meetings open to all scientists interested in research into new therapeutics. These will rotate around different organisations located in the Cambridge biotech cluster. Each two-hour session will begin with two short scientific presentations and will be followed by networking and snacks (6pm-8pm).
Attendance is free but all attendees must register in advance. Places are limited and early registration will be important to avoid disappointment!
Professor Sir Tom Blundell (University of Cambridge, Sir William Dunn Professor of Biochemistry),
Professor Patrick Maxwell (University of Cambridge, Regius Professor of Physic, Director Cambridge University Health Partners),
Professor Michael Wakelam (Babraham Institute, Director),
Professor Ewan Birney (EMBL-EBI, Associate Director),
Dr Mene Pangalos (AstraZeneca, R&D Director),
Professor Ian Wilkinson (University of Cambridge, Professor of Therapeutics; Director of CUHP’s Office for Translational Research).
Operational organising committee
Dr David Rees (Astex)
Dr Simon Cook (Babraham Institute)
Dr Ruth March (AstraZeneca)
Dr Chuck Cook (EMBL-EBI)
Dr Jana Voigt (CUHP OTR)
Financial Support is kindly provided by AstraZeneca.
Organisational Support is kindly provided by One Nucleus.
For enquiries please contact email
You can download a pdf about the Forum CamNTF_Flyer_Final.